| scholarly article | Q13442814 |
| P50 | author | Mario Paolo Colombo | Q41570231 |
| Alessia Burocchi | Q42574397 | ||
| P2093 | author name string | Silvia Piconese | |
| Andrea Gorzanelli | |||
| Paola Pittoni | |||
| P2860 | cites work | Interleukin-10: new perspectives on an old cytokine | Q24653771 |
| OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells | Q28188488 | ||
| Cancer despite immunosurveillance: immunoselection and immunosubversion | Q28263865 | ||
| The TRAIL to selective tumor death | Q28504568 | ||
| IFN regulatory factor-1 bypasses IFN-mediated antiviral effects through viperin gene induction | Q28509760 | ||
| Regulatory T cell lineage specification by the forkhead transcription factor foxp3 | Q28510328 | ||
| OX40/OX40L costimulation affects induction of Foxp3+ regulatory T cells in part by expanding memory T cells in vivo | Q28585756 | ||
| Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival | Q29547865 | ||
| How regulatory T cells work | Q29614262 | ||
| The regulation of IL-10 production by immune cells | Q29615479 | ||
| Genomic definition of multiple ex vivo regulatory T cell subphenotypes | Q33778238 | ||
| Control of immunity by the TNFR-related molecule OX40 (CD134) | Q33899607 | ||
| Distinct inflammatory signals have physiologically divergent effects on epigenetic regulation of Foxp3 expression and Treg function. | Q34158278 | ||
| Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity | Q34161493 | ||
| IL-10-secreting regulatory T cells do not express Foxp3 but have comparable regulatory function to naturally occurring CD4+CD25+ regulatory T cells | Q34318928 | ||
| CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy | Q58235013 | ||
| Characterization of Foxp3+CD4+CD25+ and IL-10-Secreting CD4+CD25+ T Cells during Cure of Colitis | Q61779891 | ||
| A non-redundant role for OX40 in the competitive fitness of Treg in response to IL-2 | Q62040086 | ||
| OX40 is differentially expressed on activated rat and mouse T cells and is the sole receptor for the OX40 ligand | Q71420856 | ||
| Engagement of the OX-40 receptor in vivo enhances antitumor immunity | Q73407121 | ||
| Regulation of transcriptional activity of the murine CD40 ligand promoter in response to signals through TCR and the costimulatory molecules CD28 and CD2 | Q73630460 | ||
| Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40 | Q77966184 | ||
| Differential CD40/CD40L expression results in counteracting antitumor immune responses | Q79717949 | ||
| The contribution of transcription factor IRF1 to the interferon-gamma-interleukin 12 signaling axis and TH1 versus TH-17 differentiation of CD4+ T cells | Q80146459 | ||
| Suppression of mature dendritic cell function by regulatory T cells in vivo is abrogated by CD40 licensing | Q80523542 | ||
| Cutting edge: OX40 inhibits TGF-beta- and antigen-driven conversion of naive CD4 T cells into CD25+Foxp3+ T cells | Q80641619 | ||
| A unique subset of CD4+CD25highFoxp3+ T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumor microenvironment | Q80726091 | ||
| Regulatory T cells expressing interleukin 10 develop from Foxp3+ and Foxp3- precursor cells in the absence of interleukin 10 | Q80785928 | ||
| Distinct and overlapping roles of interleukin-10 and CD25+ regulatory T cells in the inhibition of antitumor CD8 T-cell responses | Q81223194 | ||
| Antigen-independent signalosome of CARMA1, PKCθ, and TNF receptor-associated factor 2 (TRAF2) determines NF-κB signaling in T cells | Q34582700 | ||
| Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces | Q34590015 | ||
| Function of miR-146a in controlling Treg cell-mediated regulation of Th1 responses | Q34626052 | ||
| A therapeutic OX40 agonist dynamically alters dendritic, endothelial, and T cell subsets within the established tumor microenvironment. | Q34682173 | ||
| OX40 ligand shuts down IL-10-producing regulatory T cells | Q35016533 | ||
| IFN-inducible GTPases and immunity to intracellular pathogens | Q35920524 | ||
| OX40 costimulation turns off Foxp3+ Tregs. | Q36007580 | ||
| Cutting Edge: OX40 agonists can drive regulatory T cell expansion if the cytokine milieu is right | Q36224132 | ||
| Cytomegalovirus exploits IL-10-mediated immune regulation in the salivary glands | Q36229323 | ||
| Dendritic cells infiltrating tumors cotransduced with granulocyte/macrophage colony-stimulating factor (GM-CSF) and CD40 ligand genes take up and present endogenous tumor-associated antigens, and prime naive mice for a cytotoxic T lymphocyte respons | Q36375059 | ||
| Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody | Q36376567 | ||
| OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection | Q36537926 | ||
| Activation of NF-kappaB1 by OX40 contributes to antigen-driven T cell expansion and survival | Q36696891 | ||
| CD40L+ CD4+ memory T cells migrate in a CD62P-dependent fashion into reactive lymph nodes and license dendritic cells for T cell priming | Q36946552 | ||
| Nonredundant roles for B cell-derived IL-10 in immune counter-regulation | Q37409360 | ||
| Molecular mechanism and function of CD40/CD40L engagement in the immune system. | Q37474929 | ||
| Plasticity of CD4(+) FoxP3(+) T cells | Q37509592 | ||
| Foxp3+ regulatory T cells: differentiation, specification, subphenotypes | Q37523266 | ||
| Heterogeneity of CD4+ memory T cells: functional modules for tailored immunity | Q37578374 | ||
| OX40-OX40 ligand interaction in T-cell-mediated immunity and immunopathology. | Q37761492 | ||
| Developmental plasticity of Foxp3+ regulatory T cells | Q37786736 | ||
| Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. | Q38327926 | ||
| Selective depletion of Foxp3+ regulatory T cells improves effective therapeutic vaccination against established melanoma | Q39830418 | ||
| OX40 is required for regulatory T cell-mediated control of colitis | Q40066564 | ||
| T-regulatory cells shift from a protective anti-inflammatory to a cancer-promoting proinflammatory phenotype in polyposis | Q40909943 | ||
| The transcription factor T-bet controls regulatory T cell homeostasis and function during type 1 inflammation | Q41762357 | ||
| Reprogrammed foxp3(+) regulatory T cells provide essential help to support cross-presentation and CD8(+) T cell priming in naive mice | Q42587994 | ||
| TSLP-activated dendritic cells induce an inflammatory T helper type 2 cell response through OX40 ligand. | Q42972510 | ||
| OX40 ligand-transduced tumor cell vaccine synergizes with GM-CSF and requires CD40-Apc signaling to boost the host T cell antitumor response | Q45857323 | ||
| Triggering of OX40 (CD134) on CD4(+)CD25+ T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR. | Q45879987 | ||
| Anthrax lethal toxin enhances TNF-induced endothelial VCAM-1 expression via an IFN regulatory factor-1-dependent mechanism | Q46587215 | ||
| Hybrid Treg cells: steel frames and plastic exteriors | Q47781759 | ||
| IFN-alpha induces the human IL-10 gene by recruiting both IFN regulatory factor 1 and Stat3. | Q47817002 | ||
| Conditional regulatory T-cell depletion releases adaptive immunity preventing carcinogenesis and suppressing established tumor growth | Q50539541 | ||
| OX40 agonist therapy enhances CD8 infiltration and decreases immune suppression in the tumor. | Q51963656 | ||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 3615-3626 | |
| P577 | publication date | 2011-12-01 | |
| P1433 | published in | European Journal of Immunology | Q5412727 |
| P1476 | title | Intratumor OX40 stimulation inhibits IRF1 expression and IL-10 production by Treg cells while enhancing CD40L expression by effector memory T cells | |
| P478 | volume | 41 |
| Q56889692 | A comprehensive review on the role of co-signaling receptors and Treg homeostasis in autoimmunity and tumor immunity |
| Q42099442 | A diametric role for OX40 in the response of effector/memory CD4+ T cells and regulatory T cells to alloantigen |
| Q35427446 | Agonist antibodies to TNFR molecules that costimulate T and NK cells |
| Q39303777 | CD8+ T cell-independent tumor regression induced by Fc-OX40L and therapeutic vaccination in a mouse model of glioma. |
| Q42571627 | Convergences and divergences of thymus- and peripherally derived regulatory T cells in cancer |
| Q35922726 | Effector function of CTLs is increased by irradiated colorectal tumor cells that modulate OX-40L and 4-1BBL and is reversed following dual blockade |
| Q38749824 | Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy |
| Q48131172 | Eradication of spontaneous malignancy by local immunotherapy. |
| Q42222888 | Human OX40 tunes the function of regulatory T cells in tumor and nontumor areas of hepatitis C virus-infected liver tissue. |
| Q39235364 | Local expression of interleukin-2 by B16 melanoma cells results in decreased tumour growth and long-term tumour dormancy |
| Q38943411 | Nanoparticle formulation enhanced protective immunity provoked by PYGPI8p-transamidase related protein (PyTAM) DNA vaccine in Plasmodium yoelii malaria model |
| Q94552595 | New pathways in immune stimulation: targeting OX40 |
| Q38374889 | OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal. |
| Q33627023 | Radiation-induced modulation of costimulatory and coinhibitory T-cell signaling molecules on human prostate carcinoma cells promotes productive antitumor immune interactions |
| Q38948909 | Review on the immunotherapy strategies against metastatic colorectal carcinoma. |
| Q92534116 | T-Regulatory Cells In Tumor Progression And Therapy |
| Q53652973 | TLR2-dependent amelioration of allergic airway inflammation by parasitic nematode type II MIF in mice. |
| Q90094371 | Therapeutic strategies for the costimulatory molecule OX40 in T-cell-mediated immunity |
| Q27008946 | Treg functional stability and its responsiveness to the microenvironment |
| Q89506076 | Tumor necrosis factor receptor family costimulation increases regulatory T-cell activation and function via NF-κB |
| Q52643529 | Updates on immunotherapy for colorectal cancer. |
Search more.